Shopping Cart
Remove All
Your shopping cart is currently empty
Abituzumab (Synonyms: EMD525797, EMD 525797, DI17E6, DI 17E6)
Catalog No. T76736 Copy Product Info
🥰Excellent
Abituzumab (DI17E6) is a humanized monoclonal antibody targeting Integrin alphaV, with potential anti-cancer activity. It inhibits phosphorylation of FAK, Akt, and ERK and is used in prostate cancer research.
Abituzumab
Copy Product Info🥰Excellent
Catalog No. T76736
Synonyms EMD525797, EMD 525797, DI17E6, DI 17E6
Abituzumab (DI17E6) is a humanized monoclonal antibody targeting Integrin alphaV, with potential anti-cancer activity. It inhibits phosphorylation of FAK, Akt, and ERK and is used in prostate cancer research.
Abituzumab
Cas No. 1105038-73-0
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $197 | In Stock | In Stock | |
| 5 mg | $476 | In Stock | In Stock | |
| 10 mg | $787 | - | In Stock | |
| 25 mg | $1,170 | - | In Stock | |
| 50 mg | $1,580 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:98.44% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Abituzumab (DI17E6) is a humanized monoclonal antibody targeting Integrin alphaV, with potential anti-cancer activity. It inhibits phosphorylation of FAK, Akt, and ERK and is used in prostate cancer research. |
| In vitro | Methods: Prostate cancer cell lines were inoculated into 24-well plates and treated with Abituzumab (0.01, 0.1,1,10, 30,100μg/ml). The wound space was measured every 6 hours to observe the invasion and movement of cells. Results: Abituzumab inhibited the movement and invasion of PCa cells. Methods: Prostate cancer cell lines were treated with Abituzumab (100μg/ml) and incubated for 24h. Results: Abituzumab inhibited αV integrin expression and phosphorylation of FAK, Akt and ERK in LNCaP and C4-2B cells. [1] |
| Synonyms | EMD525797, EMD 525797, DI17E6, DI 17E6 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | Integrin aV/ITGAV/CD51 |
| Molecular Weight | 144.58 kDa |
| Cas No. | 1105038-73-0 |
| Isotype | Human IgG2 kappa |
| Recommended Isotype Control |
| Storage | -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Citations
Calculator
Preview
Related Tags: buy Abituzumab | purchase Abituzumab | Abituzumab cost | order Abituzumab | Abituzumab in vitro | Abituzumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.